Skip to main content
. 2017 Feb 7;14(2):e1002225. doi: 10.1371/journal.pmed.1002225

Fig 2. The incremental cost-effectiveness of the lung cancer screening scenarios on the efficient frontier.

Fig 2

Results are presented per 100,000 individuals alive in 2015 and are discounted by 3% annually. Scenarios on the efficient frontier are described in Table 4.